Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Agios (AGIO) Q2 2026: 442 Akvesme Prescriptions Signal Broadening Thalassemia Penetration
  July 30, 2026
• Agios Pharmaceuticals (AGIO) Q4 2025: Pyruvate Kinase Franchise Revenue Jumps 86% as Thalassemia Launch Begins
  June 15, 2026
• Agios (AGIO) Q1 2026: Acvesme Scripts Jump 450% as Rare Disease Launch Outpaces Early Expectations
  April 29, 2026
• Agios (AGIO) Q3 2025: Pyruvate Kinase Franchise Grows 44% as Thalassemia and Sickle Cell Milestones Near
  October 30, 2025
• Agios (AGIO) Q2 2025: Pyruvate Kinase Franchise Revenue Jumps 45% as Thalassemia Launch Nears
  July 31, 2025
• Agios (AGIO) Q1 2025: $1.4B Cash War Chest Sets Up Dual Rare Disease Launches
  July 04, 2025
• Agios (AGIO) Q3 2024: $1.1B Milestone Fuels Thalassemia and Sickle Cell Launch Readiness
  October 31, 2024
• Agios (AGIO) Q2 2024: $905M Royalty Monetization Secures Launch Funding for Thalassemia and Sickle Cell Pipeline
  August 01, 2024
• Agios (AGIO) Q1 2024: Energize-T Data Readout Imminent as $714M Cash Fuels Multi-Indication Thrust
  May 02, 2024
• Agios (AGIO) Q4 2023: Energize Phase 3 Delivers 42% Response, Thalassemia Launch Path in Focus
  February 15, 2024

Browse all companies